Why Novartis Is Poised to Keep Poppin'
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, Swiss pharmaceutical giant has earned a respected four-star ranking.
With that in mind, let's take a closer look at Novartis and see what CAPS investors are saying about the stock right now.
Basel, Switzerland (1895)
CEO Joseph Jimenez
CFO Harry Kirsch
Return on Equity (average, past 3 years)
$6.0 billion/$20.9 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 1,512 members who have rated Novartis believe the stock will outperform the S&P 500 going forward.
[Novartis] has an enviable strategic position with a nice pipeline of late-stage products. Diversified product lines buffer the company from difficulties in any one segment. [Novartis] also benefits from increased adoption of generic drugs. Steady, defensive big pharma play with a good margin of safety at current levels.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Novartis may not be your top choice.
If that's the case, we've compiled a special free report for investors called "Secure Your Future With 9 Rock-Solid Dividend Stocks," which uncovers several other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.
The article Why Novartis Is Poised to Keep Poppin' originally appeared on Fool.com.Fool contributor Brian Pacampara and The Motley Fool have no position in any stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.